Other studies on EBV and MS have found not only elevated antibody titres against the most prominent target EBNA1, but also significantly elevated antibody titers against targets such as EBNA3, EBNA4, EBNA6 and LMP1 (30, 31). Here, PDLIM7 is linked to myeloid sarcoma.